Todd Groessl
Publications by Year
Research Areas
Drug Transport and Resistance Mechanisms, Research on Leishmaniasis Studies, Trypanosoma species research and implications, Cell death mechanisms and regulation, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness(2016)408 cited
- → Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials(2013)408 cited
- → Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery(2011)347 cited
- → Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)(2017)225 cited
- → Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases(2020)111 cited
- → First-in-Class Pan Caspase Inhibitor Developed for the Treatment of Liver Disease(2005)106 cited
- → Characterization of IDN-6556 (3-{2-(2-tert-Butyl-phenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic Acid): a Liver-Targeted Caspase Inhibitor(2004)98 cited
- → Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis(2020)97 cited
- → Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers(2016)94 cited
- → Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease(2015)57 cited